Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140348 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
A Phase 1 study of Prostate Cancer, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT00140348: Completed Phase 1 study of Prostate Cancer, sponsored by Cell Genesys.
NCT00140348 is a Phase 1 study of Prostate Cancer that has completed, run by Cell Genesys. The registered enrollment target is 80 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140348, a Phase 1 study of Prostate Cancer, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
Conditions Studied
Interventions
- BIOLOGICAL Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Study Locations (12)
California
- South Orange County Medical Research Center - Laguna Woods
- UCSF - San Francisco
- West Coast Clinical Research - Tarzana
Washington
- Virginia Mason Med. Crt. - Seattle
- Seattle Cancer Care Alliance - Seattle
Florida
- South Florida Medical Research - Aventura
Georgia
- Emory University - Atlanta
Illinois
- Carle Cancer Center - Urbana
Indiana
- Northeast Indiana Research - Fort Wayne
Michigan
- University of Michigan Medical Center - Ann Arbor
Pennsylvania
- Fox Chase cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140348
The ClinicalTrials.gov registry entry for NCT00140348 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy allogeneic GM-CSF secreting cellular vaccine is the first listed.
NCT00140348 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Washington, Florida.
Frequently Asked Questions
What is clinical trial NCT00140348 about?
NCT00140348 is a clinical study titled "Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine". The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.
What is the current status of trial NCT00140348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2001-12. Estimated completion is 2005-04.
What conditions does trial NCT00140348 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00140348?
The interventions under investigation include: Immunotherapy allogeneic GM-CSF secreting cellular vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00140348?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00140348 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.